Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1222Lung Neoplasms 559Colorectal Neoplasms 278Breast Neoplasms 257Neoplasms 254Melanoma 236Small Cell Lung Carcinoma 233Ovarian Neoplasms 233Pancreatic Neoplasms 186Neoplasm Metastasis 171Squamous Cell Carcinoma of Head and Neck 170Carcinoma, Renal Cell 163Stomach Neoplasms 158Triple Negative Breast Neoplasms 125Head and Neck Neoplasms 121Esophageal Neoplasms 115Prostatic Neoplasms 106Urinary Bladder Neoplasms 105Colonic Neoplasms 95Uterine Cervical Neoplasms 92Endometrial Neoplasms 92Mesothelioma 84Mesothelioma, Malignant 79Carcinoma, Hepatocellular 77Sarcoma 69Carcinoma, Transitional Cell 68Kidney Neoplasms 65Carcinoma, Ovarian Epithelial 50Adenocarcinoma of Lung 47Rectal Neoplasms 45

Interventions

toripalimab 1tislelizumab 1sintilimab 1pembrolizumab 1durvalumab 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × High-Risk Resectable NSCLC × Thoracic × Clear all
NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1 Completed
27 enrolled
Thoracic

High-Risk Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡